SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation technologies, has announced that the Company’s proprietary anti-cancer technologies not only eradicated cancer in animal studies but also prevented the recurrence of the disease.
